Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07401680

A Multi-centre, Randomised Controlled Trial Comparing Fecal Microbiota Transplantation to Placebo in an Expanded Ulcerative Colitis Population: a Feasibility Study (FRONTIER-UC)

Led by University of Alberta · Updated on 2026-06-04

85

Participants Needed

2

Research Sites

39 weeks

Total Duration

On this page

Sponsors

U

University of Alberta

Lead Sponsor

U

University of Calgary

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating fecal microbiota transplantation (FMT) for patients with active ulcerative colitis (UC) in this multi-centre, randomized, double-blind, placebo-controlled feasibility trial. The goal is to see if a larger full-scale study comparing FMT to placebo in an expanded UC population is possible and practical. Participants will include adults with active UC, recruited from three Canadian healthcare centers. Participants will be assigned to one of two groups: either to add FMT capsules to their current therapy or to start or switch to a new advanced medication alongside FMT. The treatment involves oral lyophilized fecal microbiota transplantation (LFMT) capsules or placebo capsules that look identical. The dosing includes an induction phase with higher capsule counts followed by a maintenance phase over several weeks. Throughout the study, participants will take capsules daily for up to 24 weeks, beginning with an induction phase of 1 week at 4 capsules per day, then 1 week at 2 capsules per day, followed by 6 weeks at 1 capsule daily, and then a maintenance phase of 16 weeks with 1 capsule daily. Researchers will assess steroid-free endoscopic remission at 8 weeks as the primary outcome. Secondary measures include monitoring adverse events and quality of life assessments at various points. Safety and treatment effects will be closely followed during and after treatment.

CONDITIONS

Brief Title

Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Able to provide informed consent
  • Established ulcerative colitis diagnosis through standard endoscopic and histologic criteria
  • Active ulcerative colitis
  • Use of effective contraception for women of childbearing potential for at least 4 weeks prior and during the trial
  • Willing and able to comply with all required study procedures
Not Eligible

You will not qualify if you...

  • Severe ulcerative colitis requiring hospitalization
  • Diagnosis of Crohn's disease or indeterminate colitis
  • Irritable bowel syndrome
  • Intestinal infection within 4 weeks before enrollment
  • Evidence of toxic megacolon or gastrointestinal perforation on imaging
  • Planned colectomy
  • Abdominal surgery within 60 days before enrollment
  • Neutropenia with absolute neutrophil count less than 0.5 x 10^9/L
  • Peripheral white blood cell count above 35.0 x 10^9/L with fever over 38C
  • Planned or current use of another investigational product
  • Uncontrolled medical conditions such as psychiatric disorders or substance abuse
  • Severe underlying disease with expected survival less than 30 days
  • Pregnancy or breastfeeding
  • Unwillingness to stop non-dietary probiotics
  • Antibiotic use 30 days before enrollment or expected need during study
  • FMT within 6 months prior to enrollment
  • Investigator's judgment that participation is not in the best interest of the patient

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Up to 24 weeks

Participants receive lyophilized fecal microbiota transplantation or placebo capsules as adjunct or co-administration therapy for ulcerative colitis.

Daily capsule intake during induction and maintenance phases

Trial Site Locations

Total: 2 locations

1

University of Calgary

Calgary, Alberta, Canada, T2N-1N4

Not Yet Recruiting

2

University of Alberta

Edmonton, Alberta, Canada, T6G2R3

Actively Recruiting

Loading map...

Research Team

D

Dina Kao, MD,FRCPC

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

A Biospecimen Collection Study to Identify the Targets of Di...

Autoimmune Diseases

Actively Recruiting

12 locations

A Phase 2 Open-Label Extension Trial Evaluating Long-term Sa...

Crohn's Disease

Actively Recruiting

16 locations

Epidemiology, Treatment Patterns, and Healthcare Resource Us...

Inflammatory Bowel Diseases

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here